^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Talvey (talquetamab-tgvs)

    i
    Other names: JNJ-64407564, JNJ 64407564, JNJ-7564 , JNJ64407564, JNJ7564, JNJ 7564
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, GPRC5D inhibitor
    Related drugs:
    6d
    Talisman: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events (clinicaltrials.gov)
    P2, N=210, Recruiting, Janssen Research & Development, LLC | N=130 --> 210
    Enrollment change
    |
    Talvey (talquetamab-tgvs)
    8d
    Talquetamab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=2, Not yet recruiting, First Affiliated Hospital of Chongqing Medical University
    New trial
    |
    Talvey (talquetamab-tgvs)
    21d
    IFm2022-01: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Apr 2028
    Enrollment closed • Trial primary completion date • Minimal residual disease
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy (clinicaltrials.gov)
    P2, N=17, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Talvey (talquetamab-tgvs)
    1m
    KarMMa-2: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=312, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • Abecma (idecabtagene vicleucel) • Talvey (talquetamab-tgvs)
    1m
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    EMN37: Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. (2024-520433-76-00)
    P1/2, N=150, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
    New P1/2 trial
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    Talisman: A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (clinicaltrials.gov)
    P2, N=130, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Apr 2029
    Trial completion date
    |
    Talvey (talquetamab-tgvs)
    2ms
    MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2026 --> Aug 2027
    Trial completion date
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    2ms
    MonumenTAL-1: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=279, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Oct 2027
    Trial completion date • First-in-human
    |
    Talvey (talquetamab-tgvs)
    2ms
    CREATT: Multi-center, Observational Study of Teclistamab or Talquetamab in The Treatment of Multiple Myeloma Patients in China (ChiCTR2500112479)
    P4, N=200, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New P4 trial
    |
    Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    3ms
    OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
    P2, N=100, Recruiting, SCRI Development Innovations, LLC | N=75 --> 100
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)